The latest research & treatment news about Hepatitis C infection, diagnosis, symptoms and treatment.

Previous

New Treatment Recommended for Asian Chronic Hepatitis C Patients

Back to News Homepage

Next

Breaking the Hepatitis C Social Stigma

Alinia Tablets and Hepatitis C

August 24, 2007

Print this page

For HCV genotype 1 patients who have failed to respond to standard therapy (peginterferon and ribavirin), Romark Laboratories has designed a clinical trial to test the safety and effectiveness of Alinia (nitazoxanide). Learn more about the Phase II clinical trial during which nitazoxanide tablets are administered in combination with Pegasys and Copegus, in 60 patients with the most common genotype in North America.

RxTrials Institute Drug Pipeline Alert

Aug. 20, 2007 | Vol. 5 No. 163
http://fdanews.com

Romark Begins Trial of Alinia for Chronic Hepatitis C

Romark Laboratories has initiated a Phase II clinical trial of Alinia for treating chronic hepatitis C in the U.S.

According to Romark, the clinical trial is designed to evaluate the effectiveness and safety of Alinia (nitazoxanide) tablets administered in combination with Pegasys (peginterferon alfa-2a) and Copegus (ribavirin) in 60 patients with chronic hepatitis C genotype 1 who have failed to respond to standard therapy (peginterferon and ribavirin).

The trial is part of the company’s Studies to Evaluate Alinia for Treatment of Hepatitis C (STEALTH C) clinical development program, a series of clinical trials designed to evaluate the safety and efficacy of Alinia tablets in combination with peginterferon or peginterferon and ribavirin in patients with chronic hepatitis C.

The trial is designed to evaluate the effectiveness and safety of Alinia administered 500 mg twice daily for four weeks followed by Alinia-Pegasys-Copegus combination therapy for 48 weeks compared to placebo for four weeks followed by placebo-Pegasys-Copegus combination therapy for 48 weeks, which is the standard of care.

No Comments - be the first!
Share
Share

Previous

New Treatment Recommended for Asian Chronic Hepatitis C Patients

Back to News Homepage

Next

Breaking the Hepatitis C Social Stigma

Requirements for using and reposting articles

Comments

HepatitisCentral.com provides information regarding hepatitis and liver disease. Comments are available to the community in order to discuss these topics and obtain answers to questions through community members. The Editors at HepatitisCentral.com will not be responding to questions or comments posed in article comments.